Long-Term Vision ASKA VISION 2035

FY2035 Net Sales

¥150.0billion

Operating Profit Margin

15%

Women’s Healthcare × Growth Market

Building on Our Strengths in the Hormone Field, Toward the Next Stage

ASKA Pharmaceutical Holdings Long-Term Vision
「ASKA VISION 2035」

Mid-Term Management Plan 2028 Presentation Materials[PDF: 4.09MB]

Women’s Healthcare Market

Women’s healthcare market (contraception, infertility, and women’s disease-related fields) expanding at an average annual rate of approximately 3.3%*
Growth Area with Significant Unmet Needs

Women’s Healthcare Market Graph

Source: Fuji Keizai Co., Ltd. “Latest Trends and Future Outlook of the Contraception, Infertility, and Women’s Disease-Related Market” Unauthorized reproduction prohibited.
*CAGR: approximately 3.3% (2024: ¥128.6 billion – 2035 forecast: ¥184.1 billion)

Our Group’s Competitive Strengths

Why ASKA Is the Partner of Choice in This Growth Area

Deep Expertise
in the Hormone Field
  • More than 100 years of specialized experience in the hormone field
  • One of the leading market positions in Japan in the obstetrics & gynecology and thyroid fields
Long-Established
R&D Platform
  • An integrated R&D structure covering the entire process from basic research to commercialization
  • Continuous pipeline creation through a combination of in-house drug discovery and strategic licensing/acquisition
Stable
Revenue Model
  • A diversified revenue structure supported by multiple products and businesses, without dependence on any single product
  • A business model focused on specialty areas, making it less susceptible to drug price revisions and changes in market conditions

Growth Strategy

Strengthening existing businesses while expanding into new areas — from Japan to the global market

Five Pillars Driving Growth
Domestic Pharmaceutical

Addressing sexual health challenges and leading the way toward a healthier society.

Drug Discovery

Advancing the launch of in-house developed products, pipeline expansion, and overseas out-licensing through ASKA’s unique drug discovery platform.

Global

Creating value in specialty fields and strengthening our presence in global markets, primarily in Asia.

Animal Health

Contributing to the realization of sustainable animal health through unique products and solutions.

Testing and
Around-the-Pill

Contributing to total healthcare through prevention, testing/diagnosis, treatment, and prognosis management utilizing diagnostics and medical devices.

Milestones

 

Net Sales

¥71.1billion

Operating Margin

8.2%

FY2025
Mid-Term Management Plan 2028
FY2026-2028

Net Sales

¥85.0billion

Operating Margin

10%

FY2028

Deepening core strengths for sustainable growth and
building a business foundation to support global expansion

Mid-Term Management Plan 2031
FY2029-2031

Net Sales

¥100.0billion

Operating Margin

12%

FY2031

Expanding into new disease areas and establishing
a foundation for global expansion

Mid-Term Management Plan 2035
FY2032-2035

Net Sales

¥150.0billion

Operating Margin

15%

FY2035

Establishing a strong presence in global markets through
the integration of in-house developed products and group synergies

Roadmap

 
Domestic Pharmaceuticals
Drug Discovery
Global
Animal Health
Testing and
Around-the-Pill
Mid-Term Management Plan 2028
FY2026-2028
  • Aim for further growth as a leading company in women's health
  • Enter into new therapeutic areas
  • Construct a drug discovery platform that forms a unique strength in the field of gynecology
  • Build a business foundation for Hataphar and MedChoice
  • Expand operations at Hataphar's new factory and its product lineup
  • Expand the market for companion animal and livestock products
  • Tackle new challenges to expand distribution channels
  • Promote collaboration with business partners, centered on business utilizing trace analysis technologies
  • Enhance testing related to sex and aging
Mid-Term Management Plan 2031
FY2029-2031
  • In addition to women's health, tackle men's health-related diseases
  • Raise our presence in new therapeutic areas
  • Aim to be a specialty pharma company in the field of gynecology and promote collaboration and partnerships with pharmaceutical companies in Japan and overseas
  • Build the foundation for early-stage out-licensing of drug discovery seeds
  • Raise our presence as a specialty pharma company in Southeast Asia, primarily in Vietnam and the Philippines
  • Aim to be an industry-leading company in the field of endocrinology
  • Develop overseas markets, primarily in Asia
  • Create new value through collaboration between our proprietary technologies and business partners
Mid-Term Management Plan 2035
FY2032-2035
  • Become a leading company in solving health issues specific to women and to men
  • Make progress in expanding market launches, pipeline, and overseas out-licensing for in-house discovered compounds
  • Demonstrate a global presence in specialty areas
  • Achieve greater livestock production efficiency and pet well-being through competitive and unique products and solutions
  • Contribute to the achievement of a healthy and sustainable society through innovative testing, medical devices, etc

ありたい姿
2035

Aspiring Vision 2035

Purpose

We will realize a healthy tomorrow and future for all lives

ASKA VISION 2035 Concept Movie

ASKA Pharmaceutical Holdings Long-Term Vision
ASKA VISION 2035

ASKA VISION 2035
Toward a Specialty Healthcare Company Based in Japan,
Pioneering the Future Globally

Mid-Term Management Plan 2028 Presentation Materials[PDF: 4.09MB]
Related Links